FIRST TR EXCHANGE-TRADED FD - NY ARCA BIOTECH (FBT)

Historical Holders from Q1 2014 to Q4 2025

Symbol
FBT
Type / Class
Equity / NY ARCA BIOTECH
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
3,031,905
Holdings value
$544,022,410
% of all portfolios
0%
Number of holders
250
Number of buys
97
Number of sells
106
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
As of 30 Sep 2025 FIRST TR EXCHANGE-TRADED FD - NY ARCA BIOTECH (FBT) has 250 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,031,905 shares of the company stock as of 30 Sep 2025.

Institutional Holders of FIRST TR EXCHANGE-TRADED FD - NY ARCA BIOTECH (FBT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 16,695 $3,455,366 -$48,118 $206.54 6
2025 Q3 3,031,905 $544,022,410 -$12,934,226 $179.29 250
2025 Q2 3,155,408 $509,245,856 -$41,077,760 $161.33 247
2025 Q1 3,418,328 $576,824,224 +$1,866,800 $170.12 266
2024 Q4 3,420,363 $569,050,018 +$42,787,140 $166.21 251
2024 Q3 3,138,298 $539,316,109 -$51,186,933 $171.93 251
2024 Q2 3,460,734 $533,106,193 -$21,735,727 $153.99 246
2024 Q1 3,399,038 $522,621,545 -$58,318,680 $153.77 240
2023 Q4 8,422 $1,331,140 $158.06 2
2023 Q3 4,181,717 $612,007,064 -$63,886,421 $146.35 236
2023 Q2 4,610,457 $706,052,480 -$20,429,552 $153.14 245
2023 Q1 4,692,855 $727,467,897 -$18,410,603 $155.03 239
2022 Q4 4,866,125 $749,735,018 +$55,442,869 $154.13 235
2022 Q3 4,482,748 $591,950,638 +$21,647,195 $131.98 207
2022 Q2 4,312,818 $585,070,124 -$26,916,287 $135.56 213
2022 Q1 4,343,508 $647,724,445 -$78,443,092 $149.14 207
2021 Q4 4,950,684 $801,283,467 -$47,418,008 $161.96 237
2021 Q3 5,178,664 $859,824,939 -$14,094,562 $166.06 230
2021 Q2 5,217,362 $900,383,525 -$80,539,126 $172.62 226
2021 Q1 5,722,942 $918,596,937 -$20,296,161 $160.50 230
2020 Q4 5,806,131 $976,026,293 -$78,176,272 $167.99 229
2020 Q3 6,093,104 $958,533,630 -$32,867,127 $157.26 208
2020 Q2 6,228,002 $1,045,050,458 +$186,299,242 $167.77 221
2020 Q1 4,986,039 $654,316,250 -$50,953,145 $131.12 189
2019 Q4 4,678,576 $695,982,226 -$70,714,234 $148.72 202
2019 Q3 5,202,396 $644,698,213 -$825,894,353 $123.76 183
2019 Q2 12,569,450 $1,770,113,980 +$31,724,988 $140.84 215
2019 Q1 12,359,940 $1,864,465,254 +$134,154,741 $150.85 223
2018 Q4 11,613,381 $1,442,759,809 -$403,318,453 $124.20 188
2018 Q3 14,180,786 $2,246,700,672 +$1,427,829,501 $158.49 187
2018 Q2 5,133,176 $718,688,640 +$65,206,932 $140.01 153
2018 Q1 4,667,969 $620,446,822 +$88,545,487 $132.90 150
2017 Q4 3,984,500 $496,282,852 +$54,514,883 $124.57 125
2017 Q3 3,605,212 $446,710,006 +$13,792,279 $123.93 114
2017 Q2 3,491,867 $398,239,182 +$54,606,406 $114.04 111
2017 Q1 3,018,177 $316,662,504 -$6,542,034 $105.30 112
2016 Q4 3,095,174 $281,559,732 +$12,954,488 $90.87 106
2016 Q3 2,908,400 $289,306,084 -$409,358 $99.71 109
2016 Q2 3,076,251 $274,668,626 -$39,519,155 $89.43 105
2016 Q1 3,323,509 $291,884,961 -$1,883,503,957 $87.56 101
2015 Q4 21,778,403 $2,459,322,016 +$163,934,481 $113.02 126
2015 Q3 20,090,644 $2,036,625,833 +$161,945,787 $101.32 126
2015 Q2 18,453,492 $2,288,367,259 +$282,847,873 $124.02 122
2015 Q1 16,117,483 $1,905,155,132 +$447,574,728 $118.23 118
2014 Q4 12,322,255 $1,257,145,285 +$245,734,409 $102.02 108
2014 Q3 9,633,125 $883,813,866 +$85,593,538 $91.78 95
2014 Q2 8,694,763 $715,832,401 +$32,165,203 $82.33 91
2014 Q1 8,321,792 $638,198,251 +$51,685,574 $76.69 81